Peter C. Enzinger, MD | Authors

2010 Selected Sessions: GI Non-colorectal cancers

July 02, 2010

Therapeutic outcomes for patients with most of the cancers originating in the upper gastrointestinal track still remain disappointing.

Progress Reported in Advanced Esophageal Cancer

June 07, 2010

Meeting podcast: Listen to nationally regarded GI cancer specialist and clinical researcher, Peter C. Enzinger, MD, Assistant Professor of Medicine, Dana-Farber Cancer Institute, discuss new developments and trends in the management of esophageal cancer.

Irinotecan in Esophageal Cancer

December 03, 2000

Irinotecan (Camptosar) has shown activity in several solid tumor malignancies, including gastric and pancreatic cancer. In vitro studies suggest antitumor activity in esophageal cancer cell lines. Sequence-dependent synergy

Irinotecan and Cisplatin in Upper Gastrointestinal Malignancies

August 01, 1998

Irinotecan (Camptosar), an active agent in the treatment of fluorouracil-refractory colorectal cancer, has antitumor activity in upper gastrointestinal cancers. Clinical trials from Japan indicate antitumor responses in gastric and